| scholarly article | Q13442814 |
| P2093 | author name string | Abdulbari Bener | |
| Lolwa Barakat | |||
| Muzeyyen Dogan | |||
| Abdulla O A A Al-Hamaq | |||
| P2860 | cites work | Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 | Q27860575 |
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). | Q34214164 | ||
| Efficacy and safety of rosuvastatin in treatment of dyslipidemia. | Q34419733 | ||
| Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database | Q34559971 | ||
| Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation | Q34765654 | ||
| Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia--Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR) | Q35605494 | ||
| Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events | Q35752981 | ||
| Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients | Q36637890 | ||
| Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population-based study of Qatar | Q39876466 | ||
| The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals | Q41722263 | ||
| Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events | Q42167575 | ||
| Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing | Q44491215 | ||
| Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial | Q44700618 | ||
| Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study | Q44839264 | ||
| Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial | Q46545853 | ||
| Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. | Q51019297 | ||
| Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. | Q53946077 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cost-effectiveness analysis | Q1754768 |
| P304 | page(s) | 88-93 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | Indian Journal of Pharmacology | Q15710016 |
| P1476 | title | Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients | |
| P478 | volume | 46 |
| Q42762642 | Author's reply: To PMID 24550591 |
| Q42762640 | Comment: Comparison of efficacy, safety and cost-effectiveness of various statins in dyslipidemic diabetic patients |
| Q54518600 | Effets potentiels d’un modèle rationnel de prescription sur les dépenses nationales en santé: Plus d’un demi-milliard de dollars en économies annuelles. |
| Q92689968 | Efficacy and adverse reaction to different doses of atorvastatin in the treatment of type II diabetes mellitus |
| Q37174306 | Potential effects of rational prescribing on national health care spending: More than half a billion dollars in annual savings |
| Q89071830 | Stability of extemporaneously prepared rosuvastatin oral suspension |
Search more.